文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Stanton A W, Izumi T, Antoniw J W, Piper P J

Department of Pharmacology, Hunterian Institute, Royal College of Surgeons, London.

Br J Pharmacol. 1989 Jul;97(3):643-6. doi: 10.1111/j.1476-5381.1989.tb11999.x.

The actions of intravenously administered platelet-activating factor (Paf) (0.1-3.33 nmol kg-1) and the effect of a recently described Paf antagonist, WEB 2086, were investigated in the anaesthetized open-chest monkey, Macaca fascicularis. 2. Paf dose-dependently reduced blood pressure, left ventricular pressure (LVP) and its first differential LV dP/dt. 3. Mean pulmonary artery pressure, recorded in three animals, was essentially unchanged by any dose of Paf. 4. WEB 2086 (0.22 mumol kg-1, i.v.) attenuated the Paf-induced changes in BP, LVP and LV dP/dt. The dose-response curve for fall in BP was shifted to the right by one order of magnitude. 5. Histamine-induced cardiovascular changes (systemic hypotension and tachycardia) were not affected by prior administration of WEB 2086. 6. WEB 2086 should be of value in assessing the role of Paf in pathophysiological conditions.

在麻醉开胸的猕猴（食蟹猴）中研究了静脉注射血小板活化因子（PAF）（0.1 - 3.33 nmol kg-1）的作用以及最近描述的PAF拮抗剂WEB 2086的效果。2. PAF剂量依赖性地降低血压、左心室压力（LVP）及其一阶导数LV dP/dt。3. 在三只动物中记录的平均肺动脉压，无论PAF剂量如何，基本保持不变。4. WEB 2086（0.22 μmol kg-1，静脉注射）减弱了PAF诱导的血压、LVP和LV dP/dt的变化。血压下降的剂量反应曲线向右移动了一个数量级。5. 组胺诱导的心血管变化（全身性低血压和心动过速）不受预先给予WEB 2086的影响。6. WEB 2086在评估PAF在病理生理状况中的作用方面应具有价值。

Stanton A W, Izumi T, Antoniw J W, Piper P J

Department of Pharmacology, Hunterian Institute, Royal College of Surgeons, London.

Br J Pharmacol. 1989 Jul;97(3):643-6. doi: 10.1111/j.1476-5381.1989.tb11999.x.

The actions of intravenously administered platelet-activating factor (Paf) (0.1-3.33 nmol kg-1) and the effect of a recently described Paf antagonist, WEB 2086, were investigated in the anaesthetized open-chest monkey, Macaca fascicularis. 2. Paf dose-dependently reduced blood pressure, left ventricular pressure (LVP) and its first differential LV dP/dt. 3. Mean pulmonary artery pressure, recorded in three animals, was essentially unchanged by any dose of Paf. 4. WEB 2086 (0.22 mumol kg-1, i.v.) attenuated the Paf-induced changes in BP, LVP and LV dP/dt. The dose-response curve for fall in BP was shifted to the right by one order of magnitude. 5. Histamine-induced cardiovascular changes (systemic hypotension and tachycardia) were not affected by prior administration of WEB 2086. 6. WEB 2086 should be of value in assessing the role of Paf in pathophysiological conditions.

在麻醉开胸的猕猴（食蟹猴）中研究了静脉注射血小板活化因子（PAF）（0.1 - 3.33 nmol kg-1）的作用以及最近描述的PAF拮抗剂WEB 2086的效果。2. PAF剂量依赖性地降低血压、左心室压力（LVP）及其一阶导数LV dP/dt。3. 在三只动物中记录的平均肺动脉压，无论PAF剂量如何，基本保持不变。4. WEB 2086（0.22 μmol kg-1，静脉注射）减弱了PAF诱导的血压、LVP和LV dP/dt的变化。血压下降的剂量反应曲线向右移动了一个数量级。5. 组胺诱导的心血管变化（全身性低血压和心动过速）不受预先给予WEB 2086的影响。6. WEB 2086在评估PAF在病理生理状况中的作用方面应具有价值。